- Demonstrated convincingly that G-CSF decreases duration of febrile
- Patient population sampled - 89% of patients had ALL. Can these results
be generalized to the population seen here at UM?
- Study terminated early upon interim analysis which makes interpreting
secondary data more difficult. (ie. Hospital length of stay, duration
of antibiotic therapy, complications, late-onset fever).
- Appears more studies are needed to clarify if G-CSF should be used
routinely in pediatric patients admitted for F&N. It may be that
a subgroup of patients (ie. High risk, ANC <100) may benefit the
most from treatment.
MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics
with and without granulocyte colony-stimulating factor in chemotherapy-induced
febrile neutropenia: A report from the children's oncology group. Pediatr
Blood Cancer 2005; 45: 274-280.